Hypofunctional glutamatergic neurotransmission in the prefrontal cortex is involved in the emotional deficit induced by repeated treatment with phencyclidine in mice: Implications for abnormalities of glutamate release and NMDA-CaMKII signaling

Behavioural Brain Research

Volumn 180, Issue 2, 2007, Pages 152-160

  Murai, Rina ^a   Noda, Yukihiro ^a,b   Matsui, Kanae ^a,b   Kamei, Hiroyuki ^b   Mouri, Akihiro ^a   Matsuba, Kazuhisa ^b   Nitta, Astumi ^a   Furukawa, Hiroshi ^c   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Faculty of Pharmacy   (Japan)

^c MEIJO UNIVERSITY   (Japan)

Author keywords

CaMKII; Emotional deficit; Glutamate; N Methyl d aspartate; Phencyclidine; Prefrontal cortex

Indexed keywords

ASPARTIC ACID DERIVATIVE; CYCLOSERINE; DEXTRO LEVO THREO BETA BENZYLOXYASPARTATE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PHENCYCLIDINE; PROTEIN KINASE (CALCIUM,CALMODULIN) II; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; EMOTIONAL DISORDER; ENZYME RELEASE; FORCED SWIMMING TEST; GLIA CELL; IMMOBILIZATION; MALE; MOUSE; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DRUG INTERACTIONS; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY AMINO ACID TRANSPORTER 2; GENE EXPRESSION REGULATION; GLUTAMIC ACID; IMMOBILITY RESPONSE, TONIC; MALE; MICE; PHENCYCLIDINE; POTASSIUM; PREFRONTAL CORTEX; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 34248183019     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2007.03.003     Document Type: Article

References (46)

1. Allen R.M., and Young S.J. Phencyclidine-induced psychosis. Am J Psychiatry 135 (1978) 1081-1084
2. Adams B., and Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18 (1998) 5545-5554
3. Carlsson A., Hansson L.O., Waters N., and Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61 (1997) 75-94 [review]
4. Carlsson A., Waters N., and Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 46 (1999) 1388-1395 [review]
5. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1 (1988) 623-634 [review]
6. Choi D.W. Neurodegeneration: cellular defences destroyed. Nature 433 (2005) 696-698
7. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., and Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 265-275
8. Coyle J.T., Tsai G., and Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 1003 (2003) 318-327 [review]
9. Danbolt N.C. Glutamate uptake. Prog Neurobiol 65 (2001) 1-105
10. Du J., Szabo S.T., Gray N.A., and Manji H.K. Focus on CaMKII: a molecular switch in the pathophysiology and treatment of mood and anxiety disorders. Int J Neuropsychopharmacol 7 (2004) 243-248 [review]
11. Enomoto T., Noda Y., Mouri A., Shin E.J., Wang D., Murai R., et al. Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-d-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 68 (2005) 1765-1774
12. Fink C.C., and Meyer T. Molecular mechanisms of CaMKII activation in neuronal plasticity. Curr Opin Neurobiol 12 (2002) 293-299
13. Frankle W.G., Lerma J., and Laruelle M. The synaptic hypothesis of schizophrenia. Neuron 39 (2002) 205-216
14. Franklin J.B.J., and Paxinos G.T. The mouse brain. Stereotaxic coordinates (1997), Academic, New York
15. Gainetdinov R.R., Mohn A.R., and Caron M.G. Genetic animal models: focus on schizophrenia. Trend Neurosci 24 (2001) 527-533
16. Hajszan T., Leranth C., and Roth R.H. Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry 6 (2006) 639-644
17. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
18. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9 (2004) 984-997 [review]
19. Jentsch J.D., Redmond Jr. D.E., Elsworth J.D., Taylor J.R., Youngren K.D., and Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277 (1997) 953-955
20. Jebelli A.K., Doan N., and Ellison G. Prenatal phencyclidine induces heightened neurodegeneration in rats in some brain regions, especially during 2nd trimester, but possible anti-apoptotic effects in others. Pharmacol Toxicol 90 (2002) 20-25
21. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225 [review]
22. Jentsch J.D., Tran A., Le D., Youngren K.D., and Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17 (1997) 92-99
23. Johnson K.M., Phillips M., Wang C., and Kevetter G.A. Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res 52 (1998) 709-722
24. Kim J.S., Kornhuber H.H., Schmid-Burgk W., and Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20 (1980) 379-382
25. Lerner S.E., and Burns R.S. Legal issues associated with PCP abuse-the role of the forensic expert. NIDA Res Monogr 64 (1986) 229-236
26. Leonard A.S., Lim I.A., Hemsworth D.E., Horne M.C., and Hell J.W. Calcium/calmodulin-dependent protein kinase II is associated with the N-methyl-d-aspartate receptor. Proc Natl Acad Sci USA 96 (1999) 3239-3244
27. Maddox V.H., Godefroi E.F., and Parcell R.F. The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 56 (1965) 230-235
28. Mandillo S., Rinaldi A., Oliverio A., and Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 14 (2003) 533-544
29. Melone M., Vitellaro-Zuccarello L., Vallejo-Illarramendi A., Perez-Samartin A., Matute C., Cozzi A., et al. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 6 (2001) 380-386
30. Miller S., Yasuda M., Coats J.K., Jones Y., Martone M.E., and Mayford M. Disruption of dendritic translation of CaMKII alpha impairs stabilization of synaptic plasticity and memory consolidation. Neuron 36 (2002) 507-519
31. Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., and Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J. Neurosci 21 (2001) 750-757
32. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
33. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modeling schizophrenia. Curr Opin Pharmacol 5 (2005) 101-106
34. Nagai T., Yamada K., Yoshimura M., Ishikawa K., Miyamoto Y., Hashimoto K., et al. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci USA 101 (2004) 3650-3655
35. +-dependent glutamate transport. J Biomed Sci 12 (2005) 975-984
36. Noda Y., Yamada K., Furukawa H., and Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116 (1995) 2531-2537
37. Noda Y., Mamiya T., Furukawa H., and Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 324 (1997) 135-140
38. Noda Y., Kamei H., Mamiya T., Furukawa H., and Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23 (2000) 375-387
39. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., and Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 254 (1991) 1515-1518
40. Olney J.W., Newcomer J.W., and Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33 (1999) 523-533 [review]
41. Qiao H., Noda Y., Kamei H., Nagai T., Furukawa H., Miura H., et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12 (2001) 11-15
42. Rainey Jr. J.M., and Crowder M.K. Prolonged psychosis attributed to phencyclidine: report of three cases. Am J Psychiatry 132 (1975) 1076-1078
43. Ridet J.L., Malhotra S.K., Privat A., and Gage F.H. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 20 (1997) 570-577 [review]
44. Simpson M.D., Slater P., and Deakin J.F. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biol Psychiatry 44 (1998) 423-427
45. Vallejo-Illarramendi A., Torres-Ramos M., Melone M., Conti F., and Matute C. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 50 (2005) 276-279
46. Wang C., Showalter V.M., Hillman G.R., and Johnson K.M. Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain. J Neurosci Res 55 (1999) 762-769